The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
good news ,onwards and upwards
This company has developed good products but does not have the sales base. Lets hope that is now changed and we can get some money back. Does any one know its NAV seeing it has good patents.?
nice RNS for a change, people had almost forgotten this was here haha
I like !
Thomas A. Nicolette, Chief Executive Officer of ABI, commented, "We have been exploring distribution opportunities in China for our HIT screening tests and after careful consideration, partnering with Novotek's well-established sales and marketing team is the right fit for ABI. The Directors believe that Novotek's knowledge of the Territory's aggregate healthcare market and their turn-key and professional approach to product commercialisation, will provide the Company with the selling and technical support structure required for the successful introduction and rapid growth of the PIFA HIT-screening franchise in Asia's largest IVD market. The Agreement has been structured to facilitate an initial ramp up period for Novotek to conduct local clinical trials that support market approvals from the SFDA, as well as an initial, regionalised selling campaign. Aggressive, growth-oriented, market penetration plans will quickly follow as implemented by Novotek to help ensure that the Company's minimum revenue expectations are met and ultimately exceeded."
According to IVD Technology's April 2012 edition, the characteristics of the Territory's 1.3 billion population are showing trends toward an increase in health problems such as heart disease, diabetes, and cancer common in developed countries with an aging population. With this in mind, the Territory's aggregate IVD market has been estimated to exceed $2 billion with an annual growth rate of approximately 25%. With heparin being a cost-effective, anti-coagulant mainstay, especially in cardiac surgery, rapid HIT screening tests are in-demand. PIFA's entrance into Asia's largest market has already been received positively by Novotek's customer base through their pre-launch market research programs and Novatek has committed to funding the costs of obtaining State Food & Drug Administration ("SFDA") approval which will enable the product to be sold throughout China. The Agreement spans an initial 9-year period with ABI retaining the right to terminate the agreement if Novatek fails to achieve progressive minimum annual sales. Subject to the minimum sales quantities outlined in the Agreement being achieved (of which there can be no guarantee) and it not being terminated by either party, the Agreement represents a potential $33.2m minimum contribution to ABI's revenues over the initial term. However, given the size of the market opportunity and with alternative rapid HIT screening tests largely absent from the Chinese clinical laboratory market place, the eventual contribution from the Agreement has the potential to be significantly higher.
Distribution Partnership Forged in China Akers Biosciences, Inc (AIM:AKR), a leading designer and manufacturer of rapid diagnostic screening and testing products, is pleased to announce the signing of a distribution agreement ("Agreement") with Novotek Therapeutics Inc ("Novotek"), a Beijing-based pharmaceutical and in vitro diagnostic business development corporation, for ABI's innovative Particle ImmunoFiltration Assay ("PIFA") products. The multi-year agreement assigns exclusive sales and marketing rights for the products to Novotek in Mainland China ("Territory"). ABI's PIFA technology platform facilitates the rapid detection of antibodies known to be the major determinant in the pathogenesis of heparin-induced thrombocytopenia ("HIT"), a life and limb-threatening potential complication of treatment with the blood thinner, heparin. In essence, a HIT patient develops an allergy to heparin transforming the drug into a clotting agent. Individuals undergoing cardiac and major orthopaedic surgeries are especially vulnerable. The quick and accurate assessment of the patients HIT-antibody status, provided by the Company's PIFA Heparin/PF4 and the newly launched PIFA PLUSS PF4 rapid assays, is a key factor in a physician's ability to rule-out or diagnose the condition.
i am afraid the majority of those questions when you read your message back is something only you can answer for yourself. i understand where you are coming from a bit better , but surely you should realise that aim stocks are high risk/reward by there very nature , and good research is the key. as for the products they have nt mentioned , in my opinion they have been shelved to conserve cash when they needed it ,we will probably see updates regarding these soon . as i have said start up companies have a high cash burn and dont always get things right , they have messed up for sure , but now they are trying to put the jigsaw back together , so we need to give them time . maybe you should fire off an email to hq and see if they can be more helpful. i am just interpretting the situation as i see it and am happy to wait 12 months or so and see what it brings
In answer to your point about being negative Akers I’m being realistic and there are pros and cons to investing. The company has failed to deliver and as a result the share price has dropped from 21p to 1p. I brought in a 6p “not on a spike” . This happens when you invest in penny shares and the question is whether this is a viable investment at the current share price. Is their value in Akers at 1p ? In my opinion yes but it is down to their IP and not the management team. Also its only a viable investment (Short-Mid term) if there is news flow. Hence the question about what news do you see on Horizon. The Sales Team were around 18 Months ago and some sizable investors have already invested along the way “Richard Penny, Legal & General”. The fact our new investor has brought at a premium is great but he has gained voting rights and options as a result so the arrangement is in his favour, although without his investment your right we would be in a worse position/ As an investor in Akers right now I would like to know: 1. Who is this investor and what are his previous successes? a. Why has he invested (How is he going to help us) ? 2. Are they in later stage discussions with anyone in France about commercializing their breath testing range given new legislation (or is this more an observation) 3. What is happening with Blood cell Separator technology and all the other technology they have out there ? That’s just off the top of my head. I understand the fact that you are positive about the recent 30% jump but would be investors need to consider all the options. Its shouldn’t be a case of telling investors who have stuck with this company for years to simply sell up and move on just because we aren’t jumping for joy like you are, it should be a case of identifying factual evidence that things are about to change.
if you read the rns and see what they say about the opportunities and the fact they now have an active sales force for the products , then you can see the potential for large orders , especially in france with the breath scan . again the fact that somebody has parted with a large amount of cash , means he is fairly confident of a turn around as he paid over the then ask , when normally he would have got a discount on the current sp . so what does that tell you , that maybe he was given a greater deal information than is currently available to us , and he obviously liked what he heard to the tune of 30% stake in the company. if that is not a good sign for you then i honestly dont know what would be .atb
Terry I understand the importance of an Update but I don't see that news alone getting us to 2p do you ? which was why I was asking you what you expect the next big update will be. Why is that a negatative question ???
glad to see someone else on the board understands the importance of the update and the fact we now have a wealthy investor on board who will be able to bankroll the company through its key marketing phase . as you say the mcap is tiny so a decent offer would not cost much , everything to play for going forward. atb
new investor coming in . looks positive ,have noticed ii cherry picking some aim companys recently,good luck.
sorry if you are negative , why dont you sell up and go if you are hurting that much. the company is making progress , other investors think so , yet you remain sulking over your paper loss. get over it and move on
In your opinion what news are you expecting will push us up above 2p and when do you think the positive updates are likely to begin ? I can't wait
in my opinion the company is now back on an even keel and we should see a steady stream of positive updates like we did 12 months ago . i can only see this heading north from here in my opinion , how far north is anyones guess , but 2-3p would not be out of the question in a reasonable market
delayed trade 920218 at 1.08p some interest in akr.
you would not be the only one to buy in on a spike as i have done so myself many times , thinking the only way is up . my average is 1.5 so i am still behind even with the rise . to go over yesterdays point a little further , management managing to get an investor to pay over the odds for a major stake in this climate is a major achievement . if it would have been a conventional placing it would have been at a discount to the then current price and they would have therefore had to issue more shares . the guy they have on board has obviously been told more than we are privvy too , and if he feels he can throw such large amounts into the pot , then that speaks volumes . the rns was very positive and upbeat about prospects so i will not be worrying over sp direction here. as i said earlier , start up companies are expensive to run and fund, let the new products reach market and in 2 yrs you will be singing from the lamp post lol , all in my opinion of course atb
I'm not going to argue the point, I'm a shareholder afterall. The company does always seem to pull investment out the bag when the company is at threat and jobs and wages are on the line but I'm not sure how many times they can do this. I invested in this company at 6p and have given up hope on AKR. I blame poor management for their demise but hopefully the new shareholder will be able to turn things around.
Akers Biosciences, which makes diagnostic and screening products, has raised $0.45m through an investment from US entrepreneur Thomas Knox. Knox has received 30m shares for his investment, which was made at 1.50 cents per Akers share, representing a small premium to the closing mid-market price of 1.2 cents (0.75p) on the last trading day before the placing announcement. In addition Knox has provided a $0.225m 3% promissory note in exchange for 10m preferred shares at 2.25 cents each. The preferred shares are convertible at any time into common shares, at the rate of five common shares for each preferred share, for an additional payment of $0.05 per converted Preferred Share. This conversion price is equivalent to $0.0145 per commons share and, if all the preferred shares were converted, would raise an additional $0.5m. The group has also reported revenues for the half year falling from $1.09m in the first half of 2011 to $0.787m this year. Losses have also widened from $0.838 to $1.02m.
things could have been done alot worse than they have been to date . the placing has been done , capital raised from a person who knows our market and appears to have deep pockets . lets not forget that cash burn for small companies bringing new ideas to market is high . they announced they needed cash a while back , have carefully husbanded the cash we have and brought on a major investor to fall back on . they seem to be very optomistic for future sales , and focussed . that for me is good management after a disappointing start to the year . thats why i said i like the management in this company
You like the management in this company, can I just ask why ?
Outlook For the remainder of 2012, ABI has a two-fold focus aimed at delivering measurable year-end results: 1) grow the Company's HIT-screening franchise through the Q3 introduction of the PIFA PLUSS PF4 rapid test, and 2) seize the breath testing opportunities within the alcohol safety and nutraceutical industries by supporting the sales efforts of our specialized distributors. The organization is now primed for success and we are confident in the Company's ability to deliver H2 performance results that will enhance shareholder value.
Thomas A. Nicolette, President and Chief Executive Officer, commented, "The Company's goals for the first half of 2012 were to continue revenue growth for ABI's flagship products, while reducing administrative expenses and streamlining our manufacturing processes, all in preparation for the US launch of the PIFA PLUSS PF4 product line extension and increased manufacturing demand for breath alcohol detectors commencing H2 2012. "With these developments in mind, the Board of Directors is confident that the Company will accelerate revenue generation in the second half of 2012. We will expand adoption of the growing PIFA, HIT-testing product franchises through our relationships with our US distribution partners and aggressive support from our dedicated technical sales force. Discussions with distributors in Europe, the Middle East and China have also commenced and are expected to be solidified in 2012. "The recently-issued French decree requiring that each automobile be equipped with two, "NF-compliant" .05% disposable alcohol detectors is a development which is projected to generate incremental revenues in H2 2012 and beyond. The emergence of such a regulatory driver has the potential to deliver opportunities for ABI's future revenue growth given the Company's ability to quickly adjust manufacturing to meet the breath alcohol testing specifications of individual countries. We look forward to keeping our valued and ever-supportive investors abreast of our commercial progress aimed at elevating shareholder value in the short-term and into the foreseeable future."